Shares of Traws Pharma Inc (NASDAQ: TRAW) more than tripled today after reporting encouraging early-stage data for its tivoxavir marboxil as a treatment of H5N1 bird flu. The investigational drug demonstrated safety and tolerability, and maintained blood levels above the EC90 for more than 23 days in a Phase I…
Luigi Mangione, the 26-year-old accused of killing UnitedHealth CEO Brian Thompson, has pleaded not guilty to murder and terrorism…
New home sales in the United States experienced a notable rebound in November, recovering from a downturn caused by…
Tilray Inc (NASDAQ: TLRY) chief executive Irwin Simon expects the recreational use of cannabis to be legalised on a…
President Joe Biden faces a critical decision on Nippon Steel’s $15 billion bid to acquire US Steel, a deal…
Brazil wraps up 2024 in a puzzling duality: impressive economic growth on the one hand and lackluster market performance…
As the global economy moves into 2025, the optimism of a post-pandemic recovery is fading. While 2024 saw central…
US President-elect Donald Trump has demanded that Panama reduce its canal fees for American ships or face calls to…